A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas ...

Sarcopenia, a hallmark of cancer cachexia, is associated with poor outcomes in chimeric antigen receptor (CAR) T-cell therapy ...

A next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I ...

Researchers sought to assess the access to CAR-T therapy for patients within community-based and transplant cell therapy networks.

Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress for CAR T cell therapy in solid tumors One ...

A new chimeric antigen receptor (CAR) T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

Researchers at the Sant Pau Research Institute (IR Sant Pau), in collaboration with the Hospital de Sant Pau and the Josep Carreras Leukaemia Research Institute, have developed an innovative CAR-T ...

NecstGen will use Astraveus’ Lakhesys product at its facility in Leiden to determine its potential to reduce costs and increase efficiency in CAR-T manufacturing ... for cell and gene therapy ...

The study was just published in the 25th anniversary special issue of Molecular Therapy. CAR T cell therapies, which reprogram a patient's own immune cells to recognize and attack cancer ...

the flagship journal of the American Society of Gene & Cell Therapy. CAR T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer, represent a major advance ...

A new chimeric antigen receptor (CAR) T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types ...